Table of Contents Author Guidelines Submit a Manuscript
Canadian Respiratory Journal
Volume 6, Issue 5, Pages 412-416
Original Article

Similar Bronchodilation with Formoterol Delivered by Aerolizer or Turbuhaler

J Lötvall,1 A Mellén,1 P Arvidsson,1 M Palmqvist,1 P Radielovic,2 J Kottakis,3 and P Pfister2

1Department of Respiratory Medicine and Allergology, Institute of Heart and Lung Diseases, Göteborg University, Sahlgrenska University Hospital, Gothenburg, Sweden
2Clinical Development & Regulatory Affairs, Novartis Pharma, Basel, Switzerland
3Medical School, University of Crete, Greece

Copyright © 1999 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


BACKGROUND: In many countries, two dry powder formulations of inhaled formoterol are available for clinical use; one uses a single-dose device (Foradil, Aerolizer), and the other uses a multiple-dose device (Oxis, Turbuhaler).

OBJECTIVES: To study the bronchodilating effect of formoterol 12 μg when delivered via the Aerolizer and Turbuhaler devices over 12 h.

STUDY DESIGN: Randomized, double-blind, placebo controlled crossover study. Forced expiratory volume in one second (FEV1) was monitored during a 12 h period.

PATIENTS: Nineteen nonsmoking asthma patients were included in the trial on the basis of reversibility of symptoms in response to inhaled salbutamol (either 200 or 400 μg given cumulatively; minimum reversibility 15%).

RESULTS: There were no significant differences between the two dry powder devices regarding the change from baseline of FEV1 over 12 h, the area under the curve of FEV1 over 12 h or the maximum value of FEV1. The improvement in FEV1 with formoterol 12 μg versus placebo was highly significant for both devices.

CONCLUSIONS: Formoterol is similarly effective when used as a dry powder when given by either Aerolizer or the Turbuhaler.